Unite Acquisition 1 Corp.-linked Adaptin Bio opens Phase 1 trial of APTN-101 in EGFRvIII+ glioblastoma patients

• Unite Acquisition 1 Corp. disclosed that Adaptin Bio opened enrollment for a Phase 1 trial of APTN-101 in EGFRvIII-positive glioblastoma.
• No clinical results have been presented; initial safety and tolerability findings are expected later as the first-in-human study progresses.
• The trial aims to determine whether APTN-101 can be administered safely while showing early signs of anti-tumor activity.
• Duke University will run the study, supporting Adaptin’s strategy to advance a brain-delivered immunotherapy platform into the clinic.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Unite Acquisition 1 Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608201602PRIMZONEFULLFEED9813829) on August 20, 2026, and is solely responsible for the information contained therein.